

Morten Madsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284953/publications.pdf>

Version: 2024-02-01

66
papers

2,561
citations

218381

26
h-index

197535

49
g-index

66
all docs

66
docs citations

66
times ranked

3017
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 577-587.	1.8	7
2	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100301.	3.0	6
3	The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2921-e2929.	1.8	8
4	Prediction Ability of Charlson, Elixhauser, and Rx-Risk Comorbidity Indices for Mortality in Patients with Hip Fracture. A Danish Population-Based Cohort Study from 2014 to 2018. <i>Clinical Epidemiology</i> , 2022, Volume 14, 275-287.	1.5	7
5	Comorbidity and Quality of In-Hospital Care for Hip Fracture Patients. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 671-677.e4.	1.2	9
6	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
7	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20.	0.7	2
8	Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 23.	2.7	6
9	CHA 2 DS 2 -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717.	1.7	0
10	SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. <i>BMJ</i> , The, 2021, 375, e068665.	3.0	179
11	Patient-related healthcare disparities in the quality of acute hip fracture care: a 10-year nationwide population-based cohort study. <i>BMJ Open</i> , 2021, 11, e051424.	0.8	0
12	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353.	0.7	5
13	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	0.7	7
14	Risk of Myocardial Infarction in Patients Without Angiographic Coronary Artery Disease Compared With the General Population. <i>American Journal of Cardiology</i> , 2020, 132, 8-14.	0.7	3
15	Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094180.	0.9	5
16	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27.	1.8	12
17	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	1.0	32
18	<p></p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus [Response to Letter]</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 721-722.	1.5	1

#	ARTICLE	IF	CITATIONS
19	<p>Impact of the Charlson Comorbidity Index score on risk prediction by single-photon emission computed tomography myocardial perfusion imaging following myocardial infarction</p>. Clinical Epidemiology, 2019, Volume 11, 901-910.	1.5	8
20	<p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus</p>. Clinical Epidemiology, 2019, Volume 11, 419-428.	1.5	13
21	Classification and characteristics of on&label and off&label apixaban use in Denmark and Sweden. Pharmacoepidemiology and Drug Safety, 2019, 28, 867-878.	0.9	5
22	Predicting stroke in patients without atrial fibrillation. European Journal of Clinical Investigation, 2019, 49, e13103.	1.7	5
23	Association between anti-diabetes treatments and cardiovascular risk in diabetes patients with and without coronary artery disease. Diabetes and Vascular Disease Research, 2019, 16, 351-359.	0.9	8
24	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 153-158.	0.7	10
25	Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 128-131.	2.5	26
26	The Western Denmark Heart Registry. Journal of the American College of Cardiology, 2018, 71, 1259-1272.	1.2	90
27	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. European Heart Journal Cardiovascular Imaging, 2018, 19, 329-338.	0.5	5
28	Coronary stent implantation and adverse cardiac events after surgery. European Journal of Clinical Investigation, 2018, 48, e13030.	1.7	3
29	Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke, 2018, 49, 2568-2576.	1.0	50
30	Diagnostic Performance of In&Procedure Angiography&Derived Quantitative Flow Reserve Compared to Pressure&Derived Fractional Flow Reserve: The FAVOR II Europe&Japan Study. Journal of the American Heart Association, 2018, 7, .	1.6	240
31	Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. American Heart Journal. 2018. 202. 49-53.	1.2	12
32	Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER). American Heart Journal, 2018, 205, 97-109.	1.2	61
33	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 255-264.	1.1	38
34	Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care, 2017, 40, 1103-1110.	4.3	37
35	Coronary artery disease and risk of adverse cardiac events and stroke. European Journal of Clinical Investigation, 2017, 47, 819-828.	1.7	23
36	Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. Thrombosis and Haemostasis, 2016, 116, 172-180.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary intervention. <i>Clinical Epidemiology</i> , 2016, Volume 8, 415-423.	1.5	30
38	Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. <i>International Journal of COPD</i> , 2016, 11, 455.	0.9	53
39	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2622-2632.	1.2	89
40	Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. <i>Endoscopy International Open</i> , 2016, 04, E527-E533.	0.9	5
41	Invasively Measured Aortic Systolic Blood Pressure and Office Systolic Blood Pressure in Cardiovascular Risk Assessment. <i>Hypertension</i> , 2016, 68, 768-774.	1.3	11
42	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	104
43	Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on) <i>TJ ETQq1 1 0.7843 147rgBT / Overlock 10</i>		
44	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	6.3	107
45	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	6.3	96
46	Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848.	1.1	28
47	Impact of Co-morbidity on the Risk of First-Time Myocardial Infarction, Stroke, or Death After Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging. <i>American Journal of Cardiology</i> , 2014, 114, 510-515.	0.7	6
48	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. <i>EuroIntervention</i> , 2014, 10, 212-223.	1.4	8
49	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	6.3	173
50	Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. <i>Clinical Epidemiology</i> , 2013, 5, 357.	1.5	21
51	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1246-1255.	1.6	149
52	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84.	0.7	2
53	2-Year Patient-Related Versus Stent-Related Outcomes. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1140-1147.	1.2	42
54	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 812-818.	1.1	43

#	ARTICLE	IF	CITATIONS
55	Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial). American Journal of Cardiology, 2012, 110, 1585-1591.	0.7	48
56	Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 629-635.	0.7	54
57	Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. European Journal of Clinical Investigation, 2012, 42, 1047-1054.	1.7	10
58	Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). BMC Cardiovascular Disorders, 2012, 12, 18.	0.7	0
59	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. EuroIntervention, 2012, 8, 591-598.	1.4	17
60	Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy). American Journal of Cardiology, 2011, 108, 1232-1237.	0.7	39
61	Comparison of Outcomes of Patients ≥ 80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction). American Journal of Cardiology, 2011, 107, 1395-1400.	0.7	17
62	Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2010, 75, 101-108.	0.7	23
63	Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. American Journal of Cardiology, 2010, 105, 1513-1519.	0.7	41
64	Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology, 2010, 2, 137.	1.5	147
65	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, The, 2010, 375, 1090-1099.	6.3	198
66	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention, 2010, 5, 898-905.	1.4	42